Regional Pathology Services

ICD-10

For information on ICD-10 please refer to our Lab Chat Information Sheet.


Ebola Specimen Collection

Please refer to the Ebola section on the CDC's website for specific instructions on Ebola specimen collection and handling in suspected cases.


Conventry HMO Plan Types

We would like to inform our clients that we do not participate in the Methodist Health Systems or Alegent-Creighton Health (CHI) Coventry HMO Plan types.  Therefore, to ensure that your patients do not receive any unexpected statements with out-of-network charges, any laboratory charges will be billed back to our clients.


New Tests / Test Updates

1/5/16 - Kappa_Lambda Free Light Chain Assay - Lab Alert

12/2/15 - Hepatitis B Surface Antibody Testing - Lab Alert

The test kit for Hepatitis B surface antibody testing (HBSAB) is experiencing a national production backorder due to failing quality control reagents.  This backorder may last through the end of December 2015.  We are currently sending out the HBSAB tests to a reference laboratory that uses a different method with a slightly different reference range that will be included on the reports.  In addition, please note we are experiencing a minimum turn-around time of approximately 48-hours for this test from our reference laborator.

9/30/15 - QUAD Screen - Lab Alert

9/15/15 - Prealbumin Reference Interval and Speciment Requirement Changes - Lab Alert

6/26/15 - *New* - Entervirus D68 - Lab Alert

4/9/14 - Change to specimen type for Troponin I, effective 4/15/15 - Lab Alert

1/8/15 - GI Pathogen Panel - Lab Alert

Now offering the Molecular Based Gastrointestinal Panel that detects 21 targets in just one test with results in just hours (versus days) for traditional stool culture!


Personalized Medicine - Right here in Nebraska with a 50 Gene Cancer Panel!

The Nebraska Medicine Molecular Diagnostics Laboratory will be the first lab in Nebraska to offer a 50 gene cancer panel that will allow doctors to look for genetic mutations to personalize and tailor therapies for their cancer patients.  (Read the full article.)